{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:12:00Z","timestamp":1768450320793,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40261-021-01006-9","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T07:41:56Z","timestamp":1612942916000},"page":"235-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Correlations Between SGLT-2 Inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs"],"prefix":"10.1007","volume":"41","author":[{"given":"Yukari","family":"Katsuhara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunya","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"1006_CR1","unstructured":"FDA. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). 14 Jun 2016. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin. Accessed 9 July 2020."},{"key":"1006_CR2","doi-asserted-by":"crossref","unstructured":"The Committee on the Proper Use of SI. Recommendations on the proper use of SGLT2 inhibitors. Diabetology International. 2019 2019\/11\/15.","DOI":"10.1007\/s13340-019-00415-8"},{"key":"1006_CR3","unstructured":"PMDA. PMDA revises a label tofogliflozin. 9 Jan 2015. (In Japanese). https:\/\/www.info.pmda.go.jp\/kaiteip\/20150109A002\/03.pdf. Accessed 9 July 2020."},{"key":"1006_CR4","unstructured":"PMDA. PMDA revises labels ipragliflozin, dapagliflozin, luseogliflozin, canagliflozin, and empagliflozin. 9 Jan 2015. (In Japanese). https:\/\/www.info.pmda.go.jp\/kaiteip\/20150109A002\/02.pdf. Accessed 9 July 2020."},{"issue":"22","key":"1006_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"1","key":"1006_CR6","doi-asserted-by":"publisher","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","volume":"9","author":"JR Donnan","year":"2019","unstructured":"Donnan JR, Grandy CA, Chibrikov E, Marra CA, Aubrey-Bassler K, Johnston K, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019;9(1):e022577.","journal-title":"BMJ Open."},{"issue":"4","key":"1006_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/j.ajkd.2020.03.019","volume":"76","author":"C Rampersad","year":"2020","unstructured":"Rampersad C, Kraut E, Whitlock RH, Komenda P, Woo V, Rigatto C, et al. Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study. Am J Kidney Dis. 2020;76(4):471\u201391.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1006_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3820\/jjpe.14.27","volume":"14","author":"T Fujita","year":"2009","unstructured":"Fujita T. Signal detection of adverse drug reactions. Jpn J Pharmacoepidemiol. 2009;14(1):27\u201336 (in Japanese).","journal-title":"Jpn J Pharmacoepidemiol"},{"key":"1006_CR9","unstructured":"FDA. FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files. Accessed 9 July 2020."},{"key":"1006_CR10","unstructured":"PMDA. JADER. (In Japanese). https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0004.html. Accessed 9 July 2020."},{"key":"1006_CR11","unstructured":"Uppsala Monitoring Centre. VigiBase. https:\/\/www.who-umc.org\/vigibase\/vigibase\/. Accessed 20 Dec 2020."},{"key":"1006_CR12","unstructured":"EMA. EudraVigilance. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance. Accessed 20 Dec 2020."},{"key":"1006_CR13","first-page":"335","volume":"6","author":"M Narukawa","year":"2016","unstructured":"Narukawa M. Expectations for pharmacoepidemiology studies on drug risk management. Regul Sci Med Prod. 2016;6:335\u201343 (In Japanese).","journal-title":"Regul Sci Med Prod"},{"key":"1006_CR14","unstructured":"Hinomura Y, Tadenuma H, Uehara K, Hidaka T, Murakami T, Narukawa M. Comparison of the characteristics of data contained in the drug side effect database by Japanese and US regulators. Japanese Society for Pharmacoepidemiology, 19th Annual Scientific Meeting. November 16th and 17th, 2013. (In Japanese). https:\/\/www.japic.or.jp\/service\/information\/pdf\/FAERS_JADER_data_compare.pdf. Accessed 9 July 2020."},{"key":"1006_CR15","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/DDDT.S81998","volume":"9","author":"K Nomura","year":"2015","unstructured":"Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, et al. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Des Dev Ther. 2015;9:3031\u201341.","journal-title":"Drug Des Dev Ther."},{"issue":"12","key":"1006_CR16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.numecd.2017.10.011","volume":"27","author":"A Perlman","year":"2017","unstructured":"Perlman A, Heyman SN, Matok I, Stokar J, Muszkat M, Szalat A. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis. 2017;27(12):1108\u201313.","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"7","key":"1006_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40261-020-00925-3","volume":"40","author":"Y Katsuhara","year":"2020","unstructured":"Katsuhara Y, Ogawa T. Acute renal failure, ketoacidosis, and urogenital tract infections with SGLT2 inhibitors: signal detection using a Japanese spontaneous reporting database. Clin Drug Investig. 2020;40(7):645\u201352.","journal-title":"Clin Drug Investig"},{"issue":"12","key":"1006_CR18","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.numecd.2017.10.008","volume":"27","author":"E Raschi","year":"2017","unstructured":"Raschi E, Parisotto M, Forcesi E, La Placa M, Marchesini G, De Ponti F, et al. Adverse events with sodium-glucose co-transporter-2 inhibitors: a global analysis of international spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2017;27(12):1098\u2013107.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"1006_CR19","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/dom.13255","volume":"20","author":"C Khouri","year":"2018","unstructured":"Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes Metab. 2018;20(6):1531\u20134.","journal-title":"Diabetes Obes Metab."},{"key":"1006_CR20","unstructured":"MedDRA. About MedDRA. https:\/\/www.meddra.org\/how-to-use\/support-documentation\/english\/welcome. Accessed 20 Dec 2020."},{"issue":"838","key":"1006_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejphar.2018.09.019","volume":"5","author":"V Tsimihodimos","year":"2018","unstructured":"Tsimihodimos V, Filippas-Ntekouan S, Elisaf M. SGLT1 inhibition: pros and cons. Eur J Pharmacol. 2018;5(838):153\u20136.","journal-title":"Eur J Pharmacol."},{"issue":"3","key":"1006_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","volume":"53","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213\u201325.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1006_CR23","doi-asserted-by":"publisher","first-page":"e0234065","DOI":"10.1371\/journal.pone.0234065","volume":"15","author":"J Heyward","year":"2020","unstructured":"Heyward J, Mansour O, Olson L, Singh S, Alexander GC. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis. PLoS ONE. 2020;15(6):e0234065.","journal-title":"PLoS ONE"},{"issue":"6","key":"1006_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00125-019-4835-z","volume":"62","author":"L Potier","year":"2019","unstructured":"Potier L, Roussel R, Velho G, Saulnier PJ, Bumbu A, Matar O, et al. Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. Diabetologia. 2019;62(6):939\u201347.","journal-title":"Diabetologia"},{"issue":"3","key":"1006_CR25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/dom.13130","volume":"20","author":"GP Fadini","year":"2018","unstructured":"Fadini GP, Bonora BM, Mayur S, Rigato M, Avogaro A. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018;20(3):740\u20134.","journal-title":"Diabetes Obes Metab."},{"key":"1006_CR26","unstructured":"FDA. Highlights of prescribing information invokana (Canagliflozin). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204042s027lbl.pdf. Accessed 20 Dec 2020."},{"issue":"3","key":"1006_CR27","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1159\/000489913","volume":"43","author":"K Wang","year":"2018","unstructured":"Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43(3):768\u201379.","journal-title":"Kidney Blood Press Res"},{"issue":"6","key":"1006_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/ggi.13276","volume":"18","author":"T Ishida","year":"2018","unstructured":"Ishida T, Oh A, Hiroi S, Shimasaki Y, Tsuchihashi T. Current use of antihypertensive drugs in Japanese patients with hypertension: analysis by age group. Geriatr Gerontol Int. 2018;18(6):899\u2013906.","journal-title":"Geriatr Gerontol Int."},{"key":"1006_CR29","doi-asserted-by":"publisher","first-page":"117954681983941","DOI":"10.1177\/1179546819839418","volume":"13","author":"A Gu","year":"2019","unstructured":"Gu A, Farzadeh SN, Chang YJ, Kwong A, Lam S. Patterns of antihypertensive drug utilization among US adults with diabetes and comorbid hypertension: the National Health and Nutrition Examination Survey 1999\u20132014. Clin Med Insights Cardiol. 2019;13:1179546819839418.","journal-title":"Clin Med Insights Cardiol."},{"issue":"1","key":"1006_CR30","first-page":"19","volume":"10","author":"T Yamazaki","year":"2011","unstructured":"Yamazaki T. A new topic for renin\u2013angiotensin system inhibitors angiotensin converting enzyme inhibitor. Angiol Front. 2011;10(1):19\u201323.","journal-title":"Angiol Front"},{"issue":"7551","key":"1006_CR31","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","volume":"332","author":"SE McDowell","year":"2006","unstructured":"McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332(7551):1177\u201381.","journal-title":"BMJ"},{"issue":"3","key":"1006_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","volume":"41","author":"A Szalat","year":"2018","unstructured":"Szalat A, Perlman A, Muszkat M, Khamaisi M, Abassi Z, Heyman SN. Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf. 2018;41(3):239\u201352.","journal-title":"Drug Saf"},{"issue":"1","key":"1006_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40264-019-00873-8","volume":"43","author":"TM Patek","year":"2020","unstructured":"Patek TM, Teng C, Kennedy KE, Alvarez CA, Frei CR. Comparing acute kidney injury reports among antibiotics: a pharmacovigilance study of the FDA adverse event reporting system (FAERS). Drug Saf. 2020;43(1):17\u201322.","journal-title":"Drug Saf"},{"issue":"5","key":"1006_CR34","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00280-020-04151-8","volume":"86","author":"Q Fan","year":"2020","unstructured":"Fan Q, Ma J, Zhang B, Li Q, Liu F, Zhao B. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system. Cancer Chemother Pharmacol. 2020;86(5):655\u201362.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1006_CR35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/phar.2152","volume":"38","author":"HK Welch","year":"2018","unstructured":"Welch HK, Kellum JA, Kane-Gill SL. Drug-associated acute kidney injury identified in the United States Food and Drug administration adverse event reporting system database. Pharmacotherapy. 2018;38(8):785\u201393.","journal-title":"Pharmacotherapy."},{"issue":"10","key":"1006_CR36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases the notoriety bias. Drug Saf. 2007;30(10):891\u20138.","journal-title":"Drug Saf"},{"issue":"4","key":"1006_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00592-011-0340-7","volume":"50","author":"E Raschi","year":"2013","unstructured":"Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol. 2013;50(4):569\u201377.","journal-title":"Acta Diabetol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01006-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-021-01006-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01006-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T05:25:08Z","timestamp":1615353908000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-021-01006-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1006"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01006-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"assertion":[{"value":"23 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no specific funding for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yukari Katsuhara is an employee of Takeda Pharmaceutical Company Limited and had been on leave during the research period. Shunya Ikeda has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study used anonymized information from the database, which is open to the public; therefore, in accordance with the 1964 Helsinki Declaration (and its amendments), institutional ethics approval was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study used anonymized information from the database, which is open to the public; therefore, in accordance with the 1964 Helsinki Declaration (and its amendments), institutional ethics approval was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets analyzed in this study are available in the FDA Adverse Event Reporting System (FAERS):","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Both authors were investigators in the study and participated in the study design, interpretation of the study results, and in the drafting, critical revision, and approval of the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}}]}}